# Immuno-Targeted Therapy Plus Low-Dose Chemotherapy for Newly Diagnosed Adult Ph-Negative B-ALL: A Prospective Umbrella Trial

> **NCT07643103** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 32 (estimated)

## Conditions studied

- Ph- Acute Lymphoblastic Leukemia (Ph-ALL)

## Interventions

- **DRUG:** Inotuzumab Ozogamicin (IO)
- **DRUG:** Venetoclax
- **DRUG:** Blinatumomab
- **BIOLOGICAL:** CD19-directed chimeric antigen receptor (CAR-T) T cells
- **DRUG:** Vincristine
- **DRUG:** Cyclophosphamide
- **DRUG:** Dexamethasone
- **DRUG:** Methotrexate
- **DRUG:** Cytarabine (Ara-C)
- **DRUG:** Prednisone
- **DRUG:** Mercaptopurine 50 mg

## Key facts

- **NCT ID:** NCT07643103
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-12
- **Primary completion:** 2028-05-31
- **Final completion:** 2030-05-31
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07643103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07643103, "Immuno-Targeted Therapy Plus Low-Dose Chemotherapy for Newly Diagnosed Adult Ph-Negative B-ALL: A Prospective Umbrella Trial". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07643103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*